Investors in SCYNEXIS (NASDAQ:SCYX) Have Unfortunately Lost 87% Over the Last Five Years

Yahoo Finance37minutes ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains

GlobeNewswireMay 1 04:05

323 drugs, hurry up! America is facing the biggest “drug shortage” in history...

The US now seems to be facing an unprecedented “drug shortage”...

cls.cnApr 15 14:37

Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects

TipRanksApr 11 23:15

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,

GlobeNewswireApr 10 04:05

Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership

TipRanksApr 2 18:46